Open AccessPOTENTIAL FOR IMPROVED THERAPEUTIC INDEX OF FK506 IN LIPOSOMAL FORMULATION DEMONSTRATED IN A MOUSE CARDIAC ALLOGRAFT MODEL1,2
Author(s) -
Susan Moffatt,
Vivian C. McAlister,
R. Y. Calne,
Su Metcalfe
Publication year - 1999
Publication title -
transplantation
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.45
H-Index - 204
eISSN - 1534-6080
pISSN - 0041-1337
DOI - 10.1097/00007890-199905150-00001
Subject(s) - therapeutic index , medicine , in vivo , biodistribution , immunosuppression , pharmacology , transplantation , immunosuppressive drug , drug , spleen , liposome , therapeutic effect , kidney , pharmacokinetics , blockade , heart transplantation , immunology , chemistry , biology , receptor , biochemistry , microbiology and biotechnology
FK506 is a potent immunosuppressant that has improved clinical outcomes in kidney and liver transplantation both as a primary and as a rescue immunosuppressive agent. Despite these benefits, the potential value of FK506 is limited by toxic side effects that result in a narrow therapeutic index. By encapsulating the active drug within liposomes (LipoFK506), a new formulation has been developed that might improve this therapeutic index.